Aurobindo Pharma acquires 100% stake in A1 Biochem USA for $1 million
- Aurobindo Pharma acquired 100% stake in A1 Biochem USA Inc for $1 million
- Deal completed via cash subscription on September 11, 2026
- Target entity is newly incorporated and yet to commence business operations
- Acquisition aims to expand Contract Research and Development services in the US
- Transaction classified as related-party with no promoter interest involved
*this image is generated using AI for illustrative purposes only.
Aurobindo Pharma Limited has completed the acquisition of a 100% stake in A1 Biochem USA Inc. The deal, valued at $1 million, was finalized on September 11, 2026, through a cash subscription to the target entity’s share capital.
The acquisition is part of a broader strategy to expand the company’s presence in the Contract Research and Development (CRO) sector within the United States. The target entity, incorporated on August 27, 2026, has not yet commenced business operations.
Transaction Details
The transaction was executed by A1 Biochem Labs (India) Private Limited, a step-down subsidiary of Aurobindo Pharma . The Indian subsidiary subscribed to 10,000 equity shares of $100 each, representing the initial share capital of the US entity.
| Metric | Detail |
|---|---|
| Target Entity | A1 Biochem USA Inc |
| Stake Acquired | 100% |
| Consideration | $1 million (Cash) |
| Share Structure | 10,000 equity shares of $100 each |
| Date of Completion | September 11, 2026 |
| Regulatory Approvals | None required |
Strategic Context
This move follows an earlier disclosure on July 23, 2026, regarding the acquisition of the A1 Biochem Group. The US subsidiary is designated to undertake CRO services, aligning with the parent company’s focus on pharmaceutical research and development.
As a related-party transaction, the deal involves entities within the Aurobindo group structure. A1 Biochem Labs (India) Private Limited is a subsidiary of Apitoria Pharma Private Limited, which is wholly owned by Aurobindo Pharma. The promoters and promoter group of the listed entity have no interest in this specific transaction.
What the Numbers Show
The acquisition cost of $1 million represents the entire initial capitalization of a newly incorporated entity with no prior turnover history. This suggests the investment is purely strategic, aimed at establishing a foothold in the US CRO market rather than acquiring existing revenue streams or assets from the target.
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.68% | +2.60% | +1.93% | +30.63% | +59.94% | 0.0% |
How does Aurobindo Pharma plan to accelerate the operational launch of A1 Biochem USA given its recent incorporation and lack of prior business history?
What specific CRO service segments or therapeutic areas will A1 Biochem USA prioritize to differentiate itself in the competitive US market?
Will Aurobindo Pharma seek additional capital infusions or partnerships to scale the US entity beyond the initial $1 million seed funding?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
